- New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress - Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax' COVID-19 vaccine Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will provide a first look at data from its COVID-19 influenza combination vaccine and seasonal influenza vaccine trials, at the World Vaccine Congress [ https://c212.net/c/link/?t=0&l=en&o=3507542-1&h=1840594479&u=https%3A%2F%2Fwww.terrapinn.com%2Fconference%2Fworld-vaccine-congress-washington%2Findex.stm&a=World+Vaccine+Congress ] (WVC) in Washington, DC, April 18 - 21, 2022. In addition, the latest data on its protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be presented at both WVC and the 32nd European Congress of Clinical Microbiology & Infectious Diseases [ https://c212.net/c/link/?t=0&l=en&o=3507542-1&h=1505958255&u=https%3A%2F%2Fwww.eccmid.org%2F&a=32nd+European+Congress+of+Clinical+Microbiology+%26+Infectious+Diseases ] (ECCMID) in in Lisbon, Portugal, April 23 - 26, 2022. Data from eight abstracts and presentations, including four oral presentations, will be presented across the two congresses. Gregory M. Glenn, M.D., President, Research and Development, Novavax, said: "Our presence at these two leading industry conferences shows our ongoing commitment to addressing COVID-19, and the advances we have made towards a next-generation influenza vaccine. We look forward to sharing these updates that further demonstrate the potential for our platform." Key Novavax presentations during WVC: Glenn, G How long will our immunity Panel against COVID-19 last for April 19, 2022 and will our vaccines 8:45 - 9:45 ET continue to work against VoCs? Kim, D Monitoring COVID-19 Vaccine Panel Safety under Emergency Use April 20, 2022 Authorization: Challenges 12:10 - 1:10 ET and Lessons? Glenn, G Clinical Update on Novavax's Oral Recombinant Nanoparticle Session COVID & Beyond - M4 Protein Subunit COVID-19 April 20, 2022 Vaccine as a Booster 12:40 - 1:00 ET Shinde, V Update on Novavax' NanoFlu* Oral vaccine and COVID-19 Session Influenza and -Influenza Combination Respiratory - M4 Vaccine development April 20, 2022 12:40 - 1:10 ET *NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season. Key Novavax presentations during ECCMID: Toback, S Ongoing safety and efficacy Abstract #04525 of the NVX-CoV2373 COVID-19 Oral vaccine in the United Kingdom Session Late breaking updates on COVID vaccination April 25, 2022 16:15 - 17:15 CET Shinde, V Long-term durability of Abstract #1197 antigen-specific polyfunctional Oral CD4+ T cell responses against Session Viral respiratory vaccine-homologous and infections: Influenza and RSV antigenically drifted April 26, 2022 viruses: results of a 11:00 - 12:00 CET phase III trial of a recombinant quadrivalent hemagglutinin saponin-adjuvanted nanoparticle influenza Anez, G Safety, efficacy and Abstract #04455 effectiveness of a Poster SARS-CoV-2 adjuvanted Session 12g. Vaccine recombinant spike protein development, trials, vaccine (NVX-CoV2373) efficacy, policy in a phase III trial April 25, 2022 in adolescents (PREVENT-19) 12:00 - 13:00 CET Anez, G Molecular epidemiology of Abstract #00284 SARS-CoV-2 strains identified Poster during a phase III, Session 12l. Virus efficacy and safety trial of evolution, variants, and NVX-CoV2373 vaccine impact (PREVENT-19) in the United April 25, 2022 States and Mexico 12:00 - 13:00 CET Beyhaghi, H Reported pregnancies and Abstract #01705 associated outcomes across Poster the NVX-CoV2373 COVID-19 Session 12g. Vaccine vaccine clinical development development, trials, programme efficacy, policy April 25, 2022 12:00 - 13:00 CET Marchese, A COVID-19 vaccine receptivity Abstract #04362 and preferences among Poster "vaccine hesitants" Session 12g. Vaccine development, trials, efficacy, policy April 25, 2022 12:00 - 13:00 CET For more information or to register, visit the World Vaccine Congress Washington 2022 [ https://c212.net/c/link/?t=0&l=en&o=3507542-1&h=3395465361&u=https%3A%2F%2Fwww.terrapinn.com%2Fconference%2Fworld-vaccine-congress-washington%2Findex.stm&a=World+Vaccine+Congress+Washington+2022 ] and the 32nd European Congress of Clinical Microbiology & Infectious Diseases [ https://c212.net/c/link/?t=0&l=en&o=3507542-1&h=1505958255&u=https%3A%2F%2Fwww.eccmid.org%2F&a=32nd+European+Congress+of+Clinical+Microbiology+%26+Infectious+Diseases ] websites. About Novavax Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and its quadrivalent influenza investigational vaccine candidate, previously referred to as NanoFlu. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M(TM) adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. For more information, visit www.novavax.com and connect with us on LinkedIn [ https://www.linkedin.com/company/novavax/ ] . Contacts: Investors Erika Schultz | 240-268-2022 ir@novavax.com Media Ali Chartan | 240-720-7804 Laura Keenan Lindsey | 202-709-7521 media@novavax.com SOURCE Novavax, Inc. Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg